Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading lower by 10.9% to $63.95 Monday afternoon, despite a lack of company-specific news for the session.
The stock experienced marked strength in February after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints. The stock has also experienced volatility in recent sessions after the company announced its public offering of 6.471 million common shares at $85 per share.
Is VKTX A Good Stock To Buy?
An investor can make a few decisions when deciding whether a ...
VKTX) Stock?>Full story available on Benzinga.com